2026 Jonathan Cebon: Immunology Researcher – H-Index, Publications & Awards

Discipline name	D-Index	World Ranking	Current World Ranking	National Ranking	Current National Ranking	Publications	Citations
Immunology	87	1193	1082	41	39	393	39766
Medicine	87	13421	12629	439	428	403	40011

Jonathan Cebon publication distribution in Immunology in 2026

The chart shows the distribution of publications by all Research.com ranked scientists in the field of Immunology in 2026. The highlighted bar marks where Jonathan Cebon sits on this spectrum.

62 publications 807+

This scientist: 393 publications — 80th percentile

80% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 807 publications or more.

Jonathan Cebon D-index placement in Immunology in 2026

The chart shows the D-index (discipline H-index) distribution of Immunology scientists ranked by Research.com in 2026. The highlighted bar marks where Jonathan Cebon sits on this spectrum.

40 D-Index 157+

This scientist: 87 D-Index — 76th percentile

76% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 157 D-Index or more.

Overview

Jonathan Cebon is a researcher affiliated with La Trobe University in Australia. Their work primarily spans the fields of Medicine and Immunology and Microbiology, with a significant focus on Oncology, Immunology, Molecular Biology, Surgery, and Pulmonary and Respiratory Medicine.

Their main research topics include:

Cancer Immunotherapy and Biomarkers
Immunotherapy and Immune Responses
CAR-T cell therapy research
Immune Cell Function and Interaction
Cholangiocarcinoma and Gallbladder Cancer Studies
Vaccines and immunoinformatics approaches
Ovarian cancer diagnosis and treatment

Jonathan Cebon has contributed to several journals with multiple publications in key venues such as Clinical Cancer Research, JAMA Oncology, Journal for ImmunoTherapy of Cancer, Cell Death Discovery, and Annals of Oncology.

Frequent co-authors collaborating with them include:

Andreas Behren
Matteo S. Carlino
Oliver Klein
Damien Kee
Jodie Palmer

Notable recent papers authored by Jonathan Cebon encompass the following:

Butyrophilin 2A1 is essential for phosphoantigen reactivity by γδ T cells, 2020, Science
Evaluation of Combination Nivolumab and Ipilimumab Immunotherapy in Patients With Advanced Biliary Tract Cancers, 2020, JAMA Oncology
Immunotherapy of Ipilimumab and Nivolumab in Patients with Advanced Neuroendocrine Tumors: A Subgroup Analysis of the CA209-538 Clinical Trial for Rare Cancers, 2020, Clinical Cancer Research
Blockade of the co-inhibitory molecule PD-1 unleashes ILC2-dependent antitumor immunity in melanoma, 2021, Nature Immunology
Tracking extracellular vesicle phenotypic changes enables treatment monitoring in melanoma, 2020, Science Advances

Best Publications

Overall Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma

Jedd D. Wolchok;Vanna Chiarion-Sileni;Rene Gonzalez;Piotr Rutkowski

4954
Citations
Combined BRAF and MEK Inhibition in Melanoma with BRAF V600 Mutations

Keith T. Flaherty;Jeffery R. Infante;Adil Daud;Rene Gonzalez

3234
Citations
Pan-cancer analysis of whole genomes

Peter J. Campbell;Gad Getz;Jan O. Korbel;Joshua M. Stuart

3090
Citations
Randomized Phase III Study of Temozolomide Versus Dacarbazine in the Treatment of Patients With Advanced Metastatic Malignant Melanoma

Mark R Middleton;J J Grob;N Aaronson;G Fierlbeck

1677
Citations
Whole-genome landscapes of major melanoma subtypes

Nicholas K. Hayward;Nicholas K. Hayward;James S. Wilmott;Nicola Waddell;Nicola Waddell;Peter A. Johansson

1492
Citations
Oncolytic Virotherapy Promotes Intratumoral T Cell Infiltration and Improves Anti-PD-1 Immunotherapy

Antoni Ribas;Reinhard Dummer;Igor Puzanov;Ari VanderWalde

1455
Citations
Granulocyte/macrophage colony-stimulating factor-deficient mice show no major perturbation of hematopoiesis but develop a characteristic pulmonary pathology

Edouard Stanley;Graham J. Lieschke;Graham J. Lieschke;Dianne Grail;Donald Metcalf

1093
Citations
Patterns of somatic structural variation in human cancer genomes

Yilong Li;Nicola D Roberts;Jeremiah A Wala;Jeremiah A Wala;Ofer Shapira;Ofer Shapira

942
Citations
CMTM6 maintains the expression of PD-L1 and regulates anti-tumour immunity

Marian L Burr;Marian L Burr;Marian L Burr;Christina E Sparbier;Yih-Chih Chan;James C Williamson

930
Citations
Type I IFNs Enhance the Terminal Differentiation of Dendritic Cells

Thomas Luft;Ken C Pang;Elisabeth Thomas;Paul J Hertzog

805
Citations
Recombinant NY-ESO-1 protein with ISCOMATRIX adjuvant induces broad integrated antibody and CD4(+) and CD8(+) T cell responses in humans.

Ian D. Davis;Weisan Chen;Heather Jackson;Phillip Parente;Phillip Parente

534
Citations
Functionally distinct dendritic cell (DC) populations induced by physiologic stimuli: prostaglandin E2 regulates the migratory capacity of specific DC subsets

Thomas Luft;Michael Jefford;Petra Luetjens;Tracey Toy

485
Citations
Butyrophilin 2A1 is essential for phosphoantigen reactivity by γδ T cells.

Marc Rigau;Marc Rigau;Simone Ostrouska;Thomas S Fulford;Darryl N Johnson

403
Citations
Overall Survival and Durable Responses in Patients With BRAF V600–Mutant Metastatic Melanoma Receiving Dabrafenib Combined With Trametinib

Georgina Long;Jeffrey s Weber;Jeffrey R Infante;Kevin B Kim

329
Citations
Filgrastim in Patients with Chemotherapy-Induced Febrile Neutropenia: A Double-Blind, Placebo-Controlled Trial

Darryl W. Maher;Graham J. Lieschke;Michael Green;James Bishop

311
Citations
Tumor antigen expression in melanoma varies according to antigen and stage

Catherine Barrow;Judy Browning;Duncan MacGregor;Ian D. Davis

306
Citations
Randomized, Blinded, Placebo-Controlled Phase I Trial of Pegylated Recombinant Human Megakaryocyte Growth and Development Factor With Filgrastim After Dose-Intensive Chemotherapy in Patients With Advanced Cancer

Russell L. Basser;John E.J. Rasko;Kerrie Clarke;Jonathan Cebon

296
Citations
Pooled Analysis Safety Profile of Nivolumab and Ipilimumab Combination Therapy in Patients With Advanced Melanoma.

Mario Sznol;Pier Francesco Ferrucci;David Hogg;Michael B Atkins

294
Citations
Large Scale Identification of Human Hepatocellular Carcinoma-Associated Antigens by Autoantibodies

Yu Wang;Ke-Jun Han;Xue-Wen Pang;Hilary A. Vaughan

284
Citations
Standard-dose pembrolizumab in combination with reduced-dose ipilimumab for patients with advanced melanoma (KEYNOTE-029): an open-label, phase 1b trial

Georgina V. Long;Georgina V. Long;Victoria Atkinson;Victoria Atkinson;Jonathan S. Cebon;Michael B. Jameson

282
Citations

Frequent Co-Authors

Ian D. Davis Monash University

Weisan Chen La Trobe University

Eugene Maraskovsky CSL (United Kingdom)

Georgina V. Long University of Sydney

Richard F. Kefford Macquarie University

Grant A. McArthur Peter MacCallum Cancer Centre

Matteo S. Carlino University of Sydney

Lloyd J. Old Ludwig Cancer Research

Alexander Dobrovic University of Melbourne

Andrew M. Scott La Trobe University

External Links

Personal website of Jonathan Cebon

If you think any of the details on this page are incorrect, let us know.

Related Online Degrees & Career Pathways

Studying immunology opens diverse career pathways, particularly in healthcare and research. For those interested in advanced clinical roles, pursuing an acute care NP certification can be a valuable step. This certification allows nurse practitioners to specialize in managing patients with complex conditions, complementing immunology expertise.

Nursing professionals looking to accelerate their careers can explore an accelerated NP program. These programs offer a fast-track route to becoming a nurse practitioner, combining clinical knowledge with specialized immunological skills.

For individuals without a nursing background, online accelerated nursing programs for non nurses provide an accessible pathway into nursing. These programs help bridge the gap from other fields into nursing careers, laying the groundwork for advanced studies in immunology-related healthcare roles.

Additionally, those seeking easy entry into nursing can consider absn programs with high acceptance rates. These accelerated Bachelor of Science in Nursing programs offer flexible options to start a nursing career sooner, which can pair well with further immunology specialization.